Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.43 |
| ▸ | PIM1 | P11309 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 3/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.42 |
| ▸ | CDK5R1 | Q15078 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11903939 | 0.89 | ALDH1A1 (0.44) | KDM4EALDH1A1NPC1RAB9AATM | |
| SCHEMBL11903852 | 0.89 | ALDH1A1 (0.44) | KDM4EALDH1A1NPC1RAB9AATM | |
| SCHEMBL27401952 | 0.79 | NPC1 (0.47) | KDM4EALDH1A1NPC1RAB9AATM | |
| SCHEMBL4050628 | 0.79 | ALDH1A1 (0.46) | KDM4EALDH1A1NPC1RAB9AATM | |
| SCHEMBL8864220 | 0.78 | ALDH1A1 (0.44) | KDM4EALDH1A1NPC1RAB9AATM | |
| SCHEMBL20360672 | 0.78 | TDO2 (0.52) | KDM4EALDH1A1NPC1RAB9AATM | |
| SCHEMBL28083058 | 0.76 | TOP2A (0.49) | KDM4EALDH1A1NPC1TDO2GAA | |
| SCHEMBL2498463 | 0.76 | KDM4E (0.42) | KDM4EALDH1A1NPC1RAB9AATM | |
| SCHEMBL28805994 | 0.75 | KDR (0.59) | KDM4EALDH1A1PIM1 | |
| SCHEMBL12212666 | 0.72 | HSP90AA1 (0.49) | ALDH1A1RAB9AADORA2AADORA1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10329309-B2 | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-06-25 | — | — | US | disclosed |
| US-10329309-B2 | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-06-25 | — | — | US | disclosed |
| US-10280166-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-10280166-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2019-05-07 | — | — | US | disclosed |
| US-20190119303-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2019-04-25 | — | — | US | disclosed |
| US-20190119303-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2019-04-25 | — | — | US | disclosed |
| US-20190055238-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2019-02-21 | — | — | US | disclosed |
| US-20190055238-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI PTE. LTD. (SG) | 2019-02-21 | — | — | US | disclosed |
| US-10131677-B2 | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-11-20 | — | — | US | disclosed |
| US-20180222923-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B] PYRIDINES AND THERAPEUTIC USES THEREOF | VICKERS VENTURE FUND VI (PLAN) PTE. LTD. (SG) | 2018-08-09 | — | — | US | disclosed |
| US-7615628-B2 | Imidazopyridine derivatives | RIKEN (JP) | 2009-11-10 | — | — | US | disclosed |
| US-7615628-B2 | Imidazopyridine derivatives | RIKEN (JP) | 2009-11-10 | — | — | US | disclosed |
| US-7615628-B2 | Imidazopyridine derivatives | RIKEN (JP) | 2009-11-10 | — | — | US | disclosed |
| EP-1970445-A1 | METHOD FOR NUCLEIC ACID REPLICATION AND NOVEL ARTIFICIAL BASE PAIRS | Riken (JP) | 2008-09-17 | — | — | EP | disclosed |
| US-20080125381-A1 | Imidazopyridine Derivatives | RIKEN (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20080125381-A1 | Imidazopyridine Derivatives | RIKEN (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20080125381-A1 | Imidazopyridine Derivatives | RIKEN (JP) | 2008-05-29 | — | — | US | disclosed |
| CN-101107261-A | imidazopyridine derivatives | RIKEN (JP) | 2008-01-16 | — | — | CN | disclosed |
| EP-1847546-A1 | IMIDAZOPYRIDINE DERIVATIVE | Riken (JP) | 2007-10-24 | — | — | EP | disclosed |
| EP-1847546-A1 | IMIDAZOPYRIDINE DERIVATIVE | Riken (JP) | 2007-10-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190119303-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | KDM4E 831/4885ALDH1A1 1190/4885NPC1 3809/4885 |
| US-10329309-B2 | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[4,3-B]pyridines and therapeutic uses thereof | WNT1, WNT3, WNT3A | KDM4E 1002/4885ALDH1A1 1219/4885NPC1 3440/4885 |
| US-10280166-B2 | 2-(1H-indazol-3-yl)-3H-imidazo[4,5-B]pyridine and therapeutic uses thereof | WNT1, WNT3, WNT3A | KDM4E 1881/4885ALDH1A1 710/4885NPC1 2465/4885 |
| US-10131677-B2 | 3-(3H-imidazo[4,5-B]pyridin-2-yl)-1H-pyrazolo[3,4-B]pyridine and therapeutic uses thereof | WNT1, WNT3, WNT3A | KDM4E 831/4885ALDH1A1 1190/4885NPC1 3809/4885 |
| US-20190055238-A1 | 2-(1H-INDAZOL-3-YL)-3H-IMIDAZO[4,5-B]PYRIDINE AND THERAPEUTIC USES THEREOF | WNT1, WNT3, WNT3A | KDM4E 1881/4885ALDH1A1 710/4885NPC1 2465/4885 |
| US-20180222923-A1 | 3-(3H-IMIDAZO[4,5-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B] PYRIDINES AND THERAPEUTIC USES THEREOF | WNT1, WNT3A, WNT3 | KDM4E 775/4885ALDH1A1 1034/4885NPC1 3698/4885 |
| US-20080125381-A1 | Imidazopyridine Derivatives | MKI67, IPO5, IMPA1 | KDM4E 552/4885ALDH1A1 591/4885NPC1 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.